IkappaBzeta: an emerging player in cancer.

[en] IkappaBzeta, an atypical member of the nuclear IkappaB family of proteins, is expressed at low levels in most resting cells, but is induced upon stimulation of Toll-like/IL-1 receptors through an IRAK1/IRAK4/NFkappaB-dependent pathway. Like its homolog Bcl3, IkappaBzeta can regulate the transcription of a set of inflamatory genes through its association with the p50 or p52 subunits of NF-kappaB. Long studied as a key component of the immune response, IkappaBzeta emerges as an important regulator of inflammation, cell proliferation and survival. As a result, growing evidence support the role of this transcription factor in the pathogenesis number of human hematological and solid malignancies.

Disciplines :

Genetics & genetic processes

Author, co-author :

Willems, Marie

Dubois, Nadège ; Centre Hospitalier Universitaire de Liège - CHU > Département ULiège > Faculté de médecine

Musumeci, Lucia ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences

Bours, Vincent ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine

Robe, Pierre ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Language :

English

Title :

IkappaBzeta: an emerging player in cancer.

Publication date :

2016

Journal title :

Oncotarget

eISSN :

1949-2553

Publisher :

Impact Journals, United States - New York

Volume :

Issue :

Pages :

66310-66322

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 January 2017

Statistics

Number of views

121 (7 by ULiège)

Number of downloads

153 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999 Apr;79(11-12):1828-35.
Baeuerle PA, Henkel T. Function and activation of NFkappa B in the immune system. Annu Rev Immunol. 1994;12:141-79.
Munaut C, Noël A, Hougrand O, Foidart J-M, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer. 2003 Oct 10;106(6):848-55.
Gilmore TD. NF-kappa B, KBF1, dorsal, and related matters. Cell. 1990 Sep 7;62(5):841-3.
Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006 Oct 30;25(51):6680-4.
Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS, Van Waes C. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004 Sep 15;64(18):6511-23.
Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac M-TN, Jolois O, Erkmen K, Merville M-P, Black PM, Bours V. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res. 2004 Aug 15;10(16):5595-603.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant nuclear factorkappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997 Dec 15;100(12):2952-60.
Pikarsky E, Ben-Neriah Y. NF-kappaB inhibition: a doubleedged sword in cancer? Eur J Cancer. 2006 Apr;42(6):779-84.
Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999 Nov 22;18(49):6938-47.
Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, KagnoffMF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004 Aug 6;118(3):285-96.
Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002 Nov 8;298(5596):1241-5.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004 Sep 23;431(7007):461-6.
Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville M-P, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7.
Bours V, Bonizzi G, Bentires-Alj M, Bureau F, Piette J, Lekeux P, Merville M. NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology [Internet]. 2000 Nov 16;153(1-3):27-38.
Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999 Nov 22;18(49):6853-66.
Olivier S, Robe P, Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochemical Pharmacology. 2006 Oct 30;72(9):1054-68.
Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirininduced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001 May;15(7):1273-5.
Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. MCB. 1995 Feb;15(2):943-53.
Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001;6 Suppl 2:22-8.
Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9(1):372.
Broijl A, Kersten M-J, Alemayehu WG, Levin M-D, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GMJ, Wijermans PW et al. Phase I/II trial of Weekly Bortezomib with Lenalidomide and Dexamethasone in First Relapse or Primary Refractory Myeloma. Haematologica. 2015 Dec 11.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63.
Gasparini C, Celeghini C, Monasta L, Zauli G. NF-kappaB pathways in hematological malignancies. Cell Mol Life Sci. 2014 Jun;71(11):2083-102.
Viatour P, Merville M-P, Bours V, Chariot A. Phosphorylation of NF-kappaB and IκB proteins: implications in cancer and inflammation. Trends in Biochemical Sciences. 2005 Jan;30(1):43-52.
Viatour P. GSK3-Mediated BCL-3 Phosphorylation Modulates Its Degradation and Its Oncogenicity. 2004 Sep 29;:1-11.
Park KC, Jeong J, Kim KI. Regulation of mIκBNS stability through PEST-mediated degradation by proteasome. BBRC. 2014 Jan 24;443(4):1291-5.
Kitamura H, Kanehira K, Okita K, Morimatsu M, Saito M. MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Letters. 2000 Nov 17;485(1):53-6.
Haruta H. Isolation of a Novel Interleukin-1-inducible Nuclear Protein Bearing Ankyrin-repeat Motifs. J. Biol. Chem. 2001 Mar 2;276(16):12485-8.
Shiina T, Morimatsu M, Kitamura H, Ito T, Kidou S, Matsubara K, Matsuda Y, Saito M, Syuto B. Genomic organization, chromosomal localization, and promoter analysis of the mouse Mail gene. Immunogenetics. 2001 Oct;53(8):649-55.
Chapman SJ, Khor CC, Vannberg FO, Rautanen A, Segal S, Moore CE, Davies RJO, Day NP, Peshu N, Crook DW, Berkley JA, Williams TN et al. NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun. 2009 Oct 1;11(4):319-25.
Shiina T. Targeted Disruption of MAIL, a Nuclear I B Protein, Leads to Severe Atopic Dermatitis-like Disease. J. Biol. Chem. 2004 Oct 8;279(53):55493-8.
Ueta M. Spontaneous Ocular Surface Inflammation and Goblet Cell Disappearance in I B Gene-Disrupted Mice. Investigative Ophthalmology & Visual Science. 2005 Feb 1;46(2):579-88.
Eto A, Muta T, Yamazaki S, Takeshige K. Essential roles for NF-kappaB and a Toll/IL-1 receptor domainspecific signal(s) in the induction of IκB-γ. BBRC. 2003 Feb;301(2):495-501.
Yamamoto M, Yamazaki S, Uematsu S, Sato S, Hemmi H, Hoshino K, Kaisho T, Kuwata H, Takeuchi O, Takeshige K, Saitoh T, Yamaoka S, Yamamoto N et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004 Jul 8;430(6996):218-22.
Kitamura H, Matsushita Y, Iwanaga T, Mori K, Kanehira K, Fujikura D, Morimatsu M, Saito M. Bacterial lipopolysaccharide-induced expression of the IkappaB protein MAIL in B-lymphocytes and macrophages. Arch Histol Cytol. 2003 Mar;66(1):53-62.
Yamazaki S. A Novel Ikappa B Protein, Ikappa B-zeta, Induced by Proinflammatory Stimuli, Negatively Regulates Nuclear Factor-kappa B in the Nuclei. J. Biol. Chem. 2001 May 16;276(29):27657-62.
Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997 Dec;7(6):837-47.
Irie T, Muta T, Takeshige K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Letters. 2000 Feb 11;467(2-3):160-4.
Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999 Mar 18;398(6724):252-6.
Yamazaki S. Stimulus-specific Induction of a Novel Nuclear Factor-B Regulator, I B-, via Toll/Interleukin-1 Receptor Is Mediated by mRNA Stabilization. J. Biol. Chem. 2004 Nov 1;280(2):1678-87.
Ohba T, Ariga Y, Maruyama T, Truong NK, Inoue J-I, Muta T. Identification of interleukin-1 receptor-associated kinase 1 as a critical component that induces posttranscriptional activation of IkappaB-κ. FEBS Journal. 2011 Nov 30;279(2):211-22.
Watanabe S, Takeshige K, Muta T. A cis-element in the 3'-untranslated region of IkappaB-κ mRNA governs its stimulus-specific expression. BBRC. 2007 May;356(3):785-91.
Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 1986 Aug 29;46(5):659-67.
Myer VE, Fan XC, Steitz JA. Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. EMBO J. 1997 Apr 15;16(8):2130-9.
Anant S, Davidson NO. An AU-rich sequence element (UUUN [A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability. MCB. 2000 Mar;20(6):1982-92.
Lindenblatt C, Schulze-OsthoffK, Totzke G. IkappaBzeta expression is regulated by miR-124a. Cell Cycle. 2009 Jul 1;8(13):2019-23.
Huang Y-T, Hsu T, Kelsey KT, Lin C-L. Integrative analysis of micro-RNA, gene expression, and survival of glioblastoma multiforme. Genet Epidemiol. 2015 Feb;39(2):134-43.
Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature. 1992 Aug 13;358(6387):597-9.
Hirotani T, Lee PY, Kuwata H, Yamamoto M, Matsumoto M, Kawase I, Akira S, Takeda K. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharideinduced IL-6 production in macrophages of the colonic lamina propria. J Immunol. 2005 Mar 15;174(6):3650-7.
Fiorini E, Schmitz I, Marissen WE, Osborn SL, Touma M, Sasada T, Reche PA, Tibaldi EV, Hussey RE, Kruisbeek AM, Reinherz EL, Clayton LK. Peptide-induced negative selection of thymocytes activates transcription of an NFkappa B inhibitor. Molecular Cell. 2002 Mar;9(3):637-48.
Nogai H, Wenzel S-S, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A et al. IkappaB-κ controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood. 2013 Jul 18.
Trinh DV, Zhu N, Farhang G, Kim BJ, Huxford T. The Nuclear IκB Protein IkappaBκ Specifically Binds NFkappaB p50 Homodimers and Forms a Ternary Complex on κB DNA. J. Mol. Biol. 2008 May 23;379(1):122-35.
HUXFORD T, Huang DB, Malek S, Ghosh G. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell. 1998 Dec 11;95(6):759-70.
Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NFkappaB complex. Cell. 1998 Dec 11;95(6):749-58.
Muta T, Yamazaki S, Eto A, Motoyama M, Takeshige K. IkappaB-zeta, a new anti-inflammatory nuclear protein induced by lipopolysaccharide, is a negative regulator for nuclear factor-kappaB. Journal of Endotoxin Research. 2003;9(3):187-91.
Palmer S, Chen YH. Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription. Immunol Res. 2008;42(1-3):210-8.
Motoyama M, Yamazaki S, Eto-Kimura A, Takeshige K and Muta A. Positive and Negative Regulation of Nuclear Factor-kappa B-mediated Transcription by IkappaB-zeta, an Inducible Nuclear Protein. J. Biol. Chem. 2005 Dec 16;280(9):7444-51.
Totzke. A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. J. Biol. Chem. 2010 Aug 18;281:12645-54.
Wu Z, Zhang X, Yang J, Wu G, Zhang Y, Yuan Y, Jin C, Chang Z, Wang J, Yang X, He F. Nuclear protein IkappaB-κ inhibits the activity of STAT3. BBRC. Elsevier Inc; 2009 Sep 18;387(2):348-52.
Seshadri S, Kannan Y, Mitra S, Parker-Barnes J, Wewers MD. MAIL Regulates Human Monocyte IL-6 Production. JI. 2009 Oct 2;183(8):5358-68.
Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J. Biol. Chem. 2010 May 7;285(19):14088-100.
Kao C-Y, Kim C, Huang F, Wu R. Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium. J Biol Chem. 2008 May 30;283(22):15309-18.
Hildebrand DG, Alexander E, Hörber S, Lehle S, Obermayer K, Münck N-A, Rothfuss O, Frick J-S, Morimatsu M, Schmitz I, Roth J, Ehrchen JM, Essmann F, Schulze-OsthoffK. IkappaBκ is a transcriptional key regulator of CCL2/MCP-1. JI. 2013 May 1;190(9):4812-20.
Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA, Wewers MD. IκBκ augments IL-12-and IL-18-mediated IFN-κ production in human NK cells. Blood. 2011 Mar 10;117(10):2855-63.
Raices RM, Kannan Y, Bellamkonda-Athmaram V, Seshadri S, Wang H, Guttridge DC, Wewers MD. A Novel Role for IκBκ in the Regulation of IFNκ Production. Unutmaz D, editor. PLoS ONE. 2009 Aug 26;4(8):e6776.
Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-γ-mediated transcriptional activation. Biochem J. 2007 Aug 1;405(3):605.
Yamazaki S, Matsuo S, Muta T, Yamamoto M, Akira S, Takeshige K. Gene-specific Requirement of a Nuclear Protein, I B-, for Promoter Association of Inflammatory Transcription Regulators. J. Biol. Chem. 2008 Sep 10;283(47):32404-11.
Kayama H, Ramirez-Carrozzi VR, Yamamoto M, Mizutani T, Kuwata H, Iba H, Matsumoto M, Honda K, Smale ST, Takeda K. Class-specific regulation of pro-inflammatory genes by MyD88 pathways and IkappaBzeta. J. Biol. Chem. 2008 May 2;283(18):12468-77.
Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, PfaffE, Jacob K, Sturm D, Fontebasso AM, Quang D-AK, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Feb 9;482(7384):226-31.
Lim S, Metzger E, Schüle R, Kirfel J, Buettner R. Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer. 2010 Nov 1;127(9):1991-8.
Hanihara-Tatsuzawa F, Miura H, Kobayashi S, Isagawa T, Okuma A, Manabe I, Maruyama T. Control of Tolllike receptor-mediated T cell-independent type 1 antibody responses by the inducible nuclear protein IkappaB-κ. J. Biol. Chem. 2014 Nov 7;289(45):30925-36.
Hijioka K, Matsuo S, Eto-Kimura A, Takeshige K, Muta T. Induction of the nuclear IkappaB protein IkappaB-κ upon stimulation of B cell antigen receptor. BBRC. 2007 May;356(2):476-80.
Hanihara F, Takahashi Y, Okuma A, Ohba T, Muta T. Transcriptional and post-transcriptional regulation of IkappaB-κ upon engagement of the BCR, TLRs and FcκR. Int Immunol. 2013 Sep;25(9):531-44.
Sundaram K, Mitra S, Gavrilin MA, Wewers MD. House Dust Mite Allergens Induce Monocyte IL-1β Production Triggering an IkappaBκ Dependent GMCSF Release from Human Lung Epithelial Cells. Am J Respir Cell Mol Biol. 2015 Jan 28.
Stallhofer J, Friedrich M, Konrad-Zerna A, Wetzke M, Lohse P, Glas J, Tillack-Schreiber C, Schnitzler F, Beigel F, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-a and Modulated by IL23R Genotype Status. Inflamm Bowel Dis. 2015 Aug 7.
Kohda A, Yamazaki S, Sumimoto H. DNA element downstream of the κB site in the Lcn2 promoter is required for transcriptional activation by IkappaBκ and NF-kappaB p50. Genes Cells. 2014 Aug;19(8):620-8.
Okuma A, Hoshino K, Ohba T, Fukushi S, Aiba S, Akira S, Ono M, Kaisho T, Muta T. Enhanced apoptosis by disruption of the STAT3-IkappaB-κ signaling pathway in epithelial cells induces Sjögren's syndrome-like autoimmune disease. Immunity. 2013 Mar 21;38(3):450-60.
Kerami Z, Duijvis NW, Vogels EW, van Dooren FH, Moerland PD, Velde Te AA. Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients. J Crohns Colitis. 2014 Oct 1;8(10):1208-16.
Ikeda S, Saijo S, Murayama MA, Shimizu K, Akitsu A, Iwakura Y. Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-β-induced Foxp3 expression. JI. 2014 Feb 15;192(4):1449-58.
Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, Tejasvi T, Kang HM, Allen MH, Lambert S, Stoll SW, Weidinger S, Gudjonsson JE et al. Enhanced metaanalysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:7001.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006 May 25;441(7092):431-6.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 Mar 19;140(6):883-99.
de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006 Jan;6(1):24-37.
Lin W-W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007 May;117(5):1175-83.
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50.
Martin-Olivia D, Aguilar-Quesada R, O'valle F, Muñoz-Gámez JA, Martínez-Romero R, García Del Moral R, Ruiz de Almodóvar JM, Villuendas R, Piris MA, Oliver FJ. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006 Jun 1;66(11):5744-56.
Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma. 2002 Apr;43(4):813-6.
Canoz O, Rassidakis GZ, Admirand JH, Medeiros LJ. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol. 2004 Aug;17(8):911-7.
Schlette E, Rassidakis GZ, Canoz O, Medeiros LJ. Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19. Am J Clin Pathol. 2005 Mar;123(3):465-71.
van Krieken JH, McKeithan TW, Raghoebier S, Medeiros LJ, Kluin PM, Raffeld M. Chromosomal translocation t(14;19) as indicated by bcl-3 rearrangement is a rare phenomenon in non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a molecular genetic analysis of 176 cases. Leukemia. 1990 Dec;4(12):811-2.
Maldonado V, Melendez-Zajgla J. Role of Bcl-3 in solid tumors. Mol Cancer. 2011;10:152.
Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller WJ, Clarkson RWE. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Research. 2013 Jan 15;73(2):745-55.
Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, Voce DJ, Balyasnikova IV, Zhang W, Spretz R, Nunez L, Larsen GF, Weichselbaum RR, Yamini B. Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. Cancer Research. 2015 May 15;75(10):2039-48.
Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, Tepper JE, O'Neil BH. NF-kappaB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology. 2010;78(3-4):181-8.
Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000 Feb 24;19(9):1123-31.
Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003 Dec 1;63(23):8293-301.
Kimura R, Senba M, Cutler SJ, Ralph SJ, Xiao G, Mori N. Human T Cell Leukemia Virus Type I Tax-Induced IkappaB-κ Modulates Tax-Dependent and Tax-Independent Gene Expression in T Cells. Neoplasia. 2013 Sep;15(9):1110-24.
van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R, Willemze R, Tensen CP. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol. 2012 Aug;132(8):2050-9.
Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18;127(7):869-81.
Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Haliotis T, Crump M et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin Cancer Res. 2016 May 1;22(9):2290-300.
Göransson M, Andersson MK, Forni C, Ståhlberg A, Andersson C, Olofsson A, Mantovani R, Åman P. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene. 2008 Oct 13;28(2):270-8.
Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL. The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol. 2014 Feb;35(2):1459-65.
Alexander E, Hildebrand DG, Kriebs A, Obermayer K, Manz M, Rothfuss O, Schulze-OsthoffK, Essmann F. IκBκ is a regulator of the senescence-associated secretory phenotype in DNA damage-and oncogene-induced senescence. J Cell Sci. 2013 Aug 15;126(Pt 16):3738-45.
Chai EZP, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LHK, Wang L, Goh BC, Ahn KS, Hui KM, Sethi G. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther. 2015 Oct 20.
Totzke G, Essmann F, Pohlmann S, Lindenblatt C, Jänicke RU, Schulze-OsthoffK. A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. J Biol Chem. 2006 May 5;281(18):12645-54.